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PARs are also implicated in pathophysiological processes. In the context of inflammation, PAR 2 activation promotes neutrophil recruitment in mesenteric vessels (42) , a process that is delayed in PAR 2 knockout mice (26) . In the periphery, PAR 2 mediates skin inflammation and rat paw edema, and its expression is increased during atopy (5) . In the mucosa, PAR 2 mediates the proinflammatory effects observed in the Citrobacter rodentium model of infectious colitis (17) , and PAR 2 activation induces both colitis and increased intestinal permeability (8, 29) . An increase in tryptase-positive mast cells has been observed close to the epithelium in individuals with inflammatory bowel disease (IBD) (38) , suggesting an increase in the potential for PAR 2 activation in these individuals. Additionally, microvascular leakage is a common feature of inflammation that could result in the release of various coagulation proteases, several of which can activate PAR 2 , into the surrounding tissue.
Furthermore, it is now widely recognized that individuals with long-standing colitis have an increased risk of developing colon cancer (23) . Interestingly, PAR 2 is also linked to cancer processes. For example, PAR 2 activation stimulates cell proliferation in colon cancer cells (12) and increases cyclooxygenase (COX)-2 expression and activity (i.e., increased production of prostaglandin E 2 ) in lung cancer cells (22, 47) . Both COX-2 and trypsin, which is a prototypical PAR 2 -activating proteinase, are overexpressed in several cancers, including colorectal cancer, and in both cases this expression is associated with a poor prognosis (4, 37) .
Increased COX-2 levels are observed quite early in the development of colorectal cancer. Thus, in vitro, COX-2 expression seems to correlate well with increased invasiveness and metastatic potential of colorectal cancer cells (9) , whereas human polypectomy specimens demonstrate more extensive and intensive COX-2 positivity that correlates with more severely dysplastic epithelium and with a higher grade of dysplasia, respectively (36) . Similarly, in ulcerative colitis-associated colon cancer, overexpression of COX-2 is observed early in the neoplastic progression (2) . Downstream from COX-2, the prostaglandin (PG) E 2 pathway has specifically been implicated in the development and progression of carcinomas, including those of the colon (28) . As the most predominant prostaglandin in colorectal cancer, PGE 2 stimulates colonic tumor incidence, multiplicity, and growth by promoting cell invasion, growth, and the inhibition of apoptosis (reviewed in Ref. 46 ). Finally, and most convincingly, there is good evidence that individuals who regularly take nonsteroidal antiinflammatory drugs, which are best known for their ability to inhibit COXs, have a lower relative risk of developing colonic adenomas and/or colon cancer (reviewed in Ref. 4 ). This observation has also played out well in animal models, where deletion or inhibition of COX-2 specifically (but not the constitutive COX-1 enzyme) leads to a decrease in tumor size and/or multiplicity in at least three well-known mouse models of colon cancer (reviewed in Ref. 16) .
From this information, we hypothesized that PAR 2 contributes to the progression from chronic colitis to colon cancer through regulation of COX-2 expression. Here, we show that this regulation occurs in Caco-2 colon cancer cells through metalloproteinase-dependent transactivation of the epidermal growth factor receptor and requires Src tyrosine kinase, Rho kinase, and phosphatidylinositol 3 (PI3) kinase signaling. We also show that trypsin induces epidermal growth factor receptor (EGFR)-mediated COX-2 expression in the noncancerous intestinal epithelial cell (IEC)-6 cell line.
MATERIALS AND METHODS
Cell culture. Caco-2 cells were grown in either DME/F-12 supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum, or in MEM/EBSS supplemented with nonessential amino acids, 1 mM Na-pyruvate, 2.8 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum, and kept at 37°C in a humidified 5% CO 2 incubator. Cells were used up to passage 40. In some cases, the medium was additionally supplemented with 5 g/ml plasmocin (InvivoGen, San Diego, CA), which was removed from the cells at least 2 days before treatment. Cells were seeded on plastic and grown for 6 -8 days, such that cells were at least 2 days postconfluent at the time of the experiment. IEC-6 cells were grown in DMEM high-glucose medium supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 200 mM L-glutamine, 10 mg/ml insulin, and 10% fetal bovine serum. IEC-6 cells were seeded on plastic, grown 4 days, and used up to passage 25. Media were changed every 2-3 days. All cell treatments were conducted in serum-free media following a 1-h period of serum starvation. Unless otherwise stated, cell culture reagents were purchased from HyClone (Logan, UT).
Western blotting. Cells were washed with ice-cold PBS (without magnesium or calcium, HyClone). Ice-cold Tris-EDTA lysis buffer, containing Triton X-100, protease inhibitors, and, for some experiments, SDS, was added to the cells. In experiments to assess protein phosphorylation, the phosphatase inhibitors NaF and Na 3VO4 were added to the lysis buffer. Cells were then scraped and transferred to microcentrifuge tubes and allowed to sit on ice for at least 30 min. Lysates with SDS were vortexed, whereas lysates without SDS were disrupted by probe sonication (Fisher Scientific F60 Sonic Dismembrator, 2 ϫ 5 s per sample at power level 3; Pittsburg, PA), then spun Ͼ15 000 g in a microcentrifuge for 10 min at 4°C. The protein content of the supernatant was determined via the DC Protein Assay (BioRad, Hercules, CA). A maximum of 50 g of protein from each sample was separated by electrophoresis in a Criterion XT Bis-Tris gel (Bio-Rad), followed by electrical transfer to a nitrocellulose membrane (0.2 M pore size, Bio-Rad). Membranes were blocked at room temperature for 1 h or at 4-8°C overnight in either 5% milk, 5% BSA, or the casein-based I-Block (Life Technologies, Burlington, ON, Canada), in TBS containing 0.1% Tween 20 (TBST). Primary antibodies (see Table 1 for antibodies, dilutions, and commercial sources) in TBST-based solutions were added to the membranes and incubated overnight at 4 -8°C or 1-2 h at room temperature. Membranes were washed in TBST and then incubated in the appropriate horseradish peroxidase-conjugated secondary antibody in 5% milk for 1 h at room temperature, followed by three to four additional washes in TBST. Immunolabeled protein was detected using enhanced chemiluminescence, and images were captured either on Kodak film or with a CCD camera in a Bio-Rad ChemiDoc XRS imaging station. Image analysis was performed using ImageJ software (http://rsbweb.nih.gov/ij/). PGE 2 enzyme immunosorbent assay. Cell culture supernatants were collected on ice from Caco-2 cells after a 3-h treatment with a PAR2-inactive peptide (reverse peptide, RP) or the PAR2-activating peptide 2-furoyl-LIGRLO-HN2 (2fLI) with or without the COX-2-selective inhibitor NS-398 and stored for a maximum of 2 wk at Ϫ80°C. Levels of PGE2 were detected in the thawed conditioned media using an enzyme immunosorbent assay (Cayman Chemical, Ann Arbor, MI) according to the manufacturers= instructions.
Quantitative PCR. Caco-2 cells grown either just to confluence (4 days) or to postconfluence (8 -9 days) were collected for mRNA isolation using the Qiagen RNeasy Plus Mini-kit (Qiagen, Mississauga, ON, Canada). Following mRNA isolation and spectrophotometric quantification, 1,200 ng of RNA from each sample was transcribed into cDNA using the Qiagen RT 2 First Strand Kit. cDNA (2 l) was used in a 25-l PCR mixture containing 1ϫ QuantiTect SYBR Green PCR Master Mix and 300 nM each of the forward and reverse primers for either PAR 2 or for the housekeeping gene ␤-actin. Each sample was run in triplicate. No template controls were run in duplicate for each primer set. Real-time PCR was carried out in the Applied Biosystems 7900HT Fast Real-Time PCR System (Life Technologies, Rockville, MD) with the following cycle parameters: 95°for 15 min followed by 40 cycles of 94°for 15 s, 54°for 30 s, and 72°for 30 s. PAR 2 mRNA levels were normalized to ␤-actin and expressed as 2
Ϫ⌬Ct . Primer sequences are as follows: PAR2 forward: AGT GGC ACC ATC CAA GGA AC, PAR 2 reverse: TGG AAG GAA GAC AGT GGT CA; ␤-actin forward: CGT GGG CCG CCC TAG GCA CCA, ␤-actin reverse: TTG GCC TTA GGG TTC AGG GGG.
HPLC. Conditioned medium from Caco-2 cells treated with 0.5 M 2fLI was analyzed by reverse-phase high-performance liquid chromatography (HPLC) (Vydac C-18 column; 5-40% linear acetonitrile gradient in 0.1% trifluoroacetic acid over 30 min at a flow rate of 1 ml/min), and eluted peptides were detected by their absorbance at 254 nm. As an internal calibrant, 0.5 M RP was added to the conditioned medium. Under these HPLC conditions, the RP elutes just ahead of 2fLI (11-12 min vs. 13-14 min, respectively) (Fig. 1C) . Matrix metalloproteinase activity assay. Culture media were collected from Caco-2 cells that were treated with 2fLI for 30 min or left untreated. Media (100 l) from each sample was added in duplicate to a clear-bottom, black 96-well plate containing 100 l of the fluoro- Coimmunoprecipitation. Caco-2 cells were washed in ice-cold PBS and lysed in buffer containing (in mM) 20 HEPES, 350 NaCl, 0.5 EDTA, 20 NaF, 2 Na 3VO4, 1% NP40, 20% glycerol, and protease inhibitors (aprotinin, leupeptin, and phenylmethylsulfonyl fluoride). Cells were kept on ice for at least 30 min, vortexed 10 s each, and centrifuged at 5,204 g for 10 min at 4°C. Protein content of the supernatant was determined via the DC Protein Assay (Bio-Rad). A portion of the supernatant was reserved as the whole-cell extract, whereas EGFR was captured from Ն500 g of protein from the remaining supernatant with 4 g monoclonal anti-EGFR neutralizing antibody, clone LA1, (05-101, Millipore) on a rotator overnight at 8°C. Antibody-bound EGFR was precipitated with protein A/G PLUS-agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) via rotation at 8°C for an additional 2-4 h. Samples were spun at 425 g for 60 s. Beads were washed twice with modified lysis buffer containing only 10% glycerol and 0.25% NP-40 detergent. Two more washes were conducted with modified lysis buffer containing only 175 mM NaCl, 5% glycerol, and no detergent. Residual supernatant was removed from the beads with a 25-gauge needle. Protein loading buffer containing ␤-mercaptoethanol was added to the beads, which were then boiled for 5 min. Phosphorylation of tyrosine residues on the immunoprecipitated EGFR and total levels of immunoprecipitated EGFR were determined via the Western blotting procedure outlined above.
siRNA transfection and real-time PCR. Caco-2 cells were plated on six-well plates as above and allowed to grow to postconfluence. Cells were lifted with 0.2 mM EDTA in PBS without magnesium or calcium (HyClone). Lifted cells were washed and resuspended twice in medium containing no serum or antibiotics. During the washing period, wells were supplemented with 500 l Opti-MEM reduced serum medium (Invitrogen, Burlington, ON, Canada) containing either no RNA, 50 nM siRNA directed against PAR 2 (Qiagen siRNA name: Hs_F2RL1_5), or 50 nM control scrambled siRNA. To the wells containing RNA, 5 l of Lipofectamine RNAiMax was added and allowed to sit at room temperature for 15-18 min. Resuspended cells (2 ml/well) were added back to the wells containing Opti-MEM ϩ/Ϫ RNA and returned to the culture incubator for 24 h. To examine transfection efficiency, one well that had received no RNA, one well that had received scrambled RNA, and one well that had received PAR 2 siRNA were left untreated and processed for mRNA isolation using a Qiagen RNeasy Plus Mini-kit. Following mRNA isolation and spectrophotometric quantification, 900 ng of RNA from each sample was transcribed into cDNA using an RT 2 First Strand Kit (SABiosciences, Frederick, MD). cDNA (1 l) was used in a 25-l PCR mixture containing 1ϫ QuantiTect SYBR Green PCR Master Mix and 300 nM each of the forward and reverse primers for either PAR 2 or for the housekeeping gene ␤-actin (see above for primer sequences). Each sample was run in triplicate. No template controls were run in duplicate for each primer set. Real-time PCR was carried out in the Applied Biosystems 7900HT Fast Real-Time PCR System (95°for 15 min followed by 38 cycles of 94°for 30 s, 58°for 15 s, and 72°f or 30 s). For relative quantification analysis using SDS Study Manager (Applied Biosystems), the cut-off threshold was set to 0.3, the baseline was set to 3-14, and the sample transfected with scrambled RNA was set as the calibrator sample. PAR 2 mRNA levels are expressed as 2
⌬⌬CT . Luminex assay. Caco-2 cells were left untreated or treated with 0.5 M 2fLI in the presence or absence of 3 M marimastat for 60 min. Media were collected and frozen at Ϫ80°C until ready to process. Cells were washed in ice-cold PBS and lysed in buffer containing 50 mM Tris·HCl and 2 mM EDTA. Lysates were incubated on ice, Fig. 1 . A: Caco-2 cells were grown to postconfluence and switched to serum-free media 1 h before treatments; all treatments were conducted in serum-free media. Cells were left untreated (Ctrl) or were treated with 0.5 M inactive reverse peptide (RP) or 0.5 M proteinase-activated receptor 2 (PAR2)-activating peptide 2-furoyl-LIGRLO-NH2 (2fLI) for 3 h. Cell lysates were immunoblotted for COX-2 and actin (top). Pixel density was measured, expressed as a ratio of cyclooxygenase (COX)-2/actin, and normalized to levels observed in RP-treated cells (bottom, n ϭ 4, P Ͻ 0.05 compared with RP treatment group). B: prostaglandin E2 (PGE2) levels were measured via a commercial ELISA assay in media collected from Caco-2 cells grown as in A and treated for 3 h with 0.5 M RP or 0.5 M 2fLI in the presence or absence of 10 M of the COX-2-selective inhibitor NS-398 (*P Ͻ 0.05 as shown). C: Caco-2 cells, grown as above, were treated for 3 h with either 0.5 M RP or 0.5 M 2fLI. Cell lysates were immunoblotted for COX-1 and actin (top), and pixel density was expressed as a ratio of COX-1/actin (bottom, n ϭ 5). D: Caco-2 cells were grown until just confluent (4 days) or until 4 -5 days postconfluent (8 -9 days). PAR2 mRNA levels were assessed by quantitative PCR and normalized to ␤-actin; ****P Ͻ 0.0001 compared with mRNA levels in cells grown for 8 -9 days, n ϭ 3-4.
sonicated, and then clarified by centrifugation as above. Supernatants were frozen at Ϫ80°C until ready to process. A multiplex assay was performed (Eve Technologies, Calgary, AB) on both media and lysates using the EMD4Biosciences Widescreen Human Cancer Panel 2 (EMD Chemicals, Gibbstown, NJ) according to the manufacturer's instructions.
Amphiregulin ELISA. Caco-2 cells were treated with 10 g/ml monoclonal anti-EGFR neutralizing antibody, clone LA1, (05-101, Millipore) for 20 -30 min. This was followed by treatment with either 0.5 M RP or with 0.5 M 2fLI in the presence or absence of 3 M marimastat for 40 min. Media were collected and frozen at Ϫ80°C until ready for processing. Levels of amphiregulin were detected in the conditioned media using an ELISA assay (RayBiotech, Norcross, GA) according to the manufacturers' instructions.
Drugs and reagents. The PAR 2-activating peptide, 2-furoyl-LI-GRLO-NH2, as well as the inactive reverse peptide, 2-furoyl-OLR-GIL-NH2, were synthesized by Dr. Denis McMaster (Peptide Core Facility at the University of Calgary, Calgary, AB, Canada). Peptides were solubilized in HEPES buffer, and subsequent dilutions were made in PBS lacking magnesium or calcium (HyClone). Porcine pancreatic trypsin was purchased from Sigma-Aldrich Canada (no. T0303; Oakville, ON, Canada) and reconstituted in sterile PBS (HyClone). Recombinant human MMP-9 was purchased from R&D Systems and dissolved in a buffer containing (in mM) 50 Tris, 10 CaCl 2, 150 NaCl, and 0.05% Brij-35. Before use, MMP aliquots were activated by incubation at 37°C for 3 h with 1 mM p-aminophenylmercuric acetate. Recombinant human EGF was purchased from R&D Systems. Inhibitor sources and solvents are as follows: ARP-100 (Tocris Biosciences, Ellisville, MO; DMSO, with further dilutions in PBS), LY294002 (Cayman Chemical; DMSO), marimastat (Tocris; water), PD153035 (Calbiochem, Gibbstown, NJ, or Tocris; DMSO), PD98059 (Sigma; DMSO), PP2 (Calbiochem; DMSO), SB202190 (Sigma; DMSO), tissue inhibitor of metalloproteinase (TIMP)-1 (R&D Systems; water), U0126 (Sigma; DMSO), and Y27632 (Tocris; PBS).
Statistical analyses. Graph columns display the means Ϯ SE, except when noted. Two comparisons were made using a Student's t-test for significance. Three or more comparisons were made using a one-way ANOVA, followed by a post hoc Tukey or Newman-Keuls test for significance. A P value of Ͻ0.05 was considered significant. 2 production in response to PAR 2 activation. Caco-2 cells were grown 3-5 days postconfluence and switched to serumfree medium 1 h before experiments. Addition of 0.5 M of the PAR 2 -activating peptide, 2fLI, for 3 h led to an increase in cellular COX-2 protein levels that was not observed in untreated cells or in response to addition of the inactive RP (Fig.  1A) . PAR 2 activation for 3 h also led to an increase in levels of PGE 2 detected in the cell culture supernatant, an effect that was abolished in the presence of the COX-2 inhibitor NS-398 (Fig.  1B) . Furthermore, no increase in the expression of the constitutive COX-1 enzyme was detected following PAR 2 activation for 3 h (Fig. 1C) . The effect of PAR 2 activation on COX-2 expression was only observed in cells that were postconfluent, as initial experiments in which cells had been grown just until confluent (3-4 days) did not show an increase in COX-2 expression following PAR 2 activation (data not shown). This result likely reflects an increase in the level of PAR 2 expression as Caco-2 cells differentiate because cells grown for only 4 days had a threefold lower level of PAR 2 mRNA compared with cells that had been grown 8 -9 days (Fig. 1D) .
RESULTS

Caco-2 colon cancer cells increase COX-2 expression and PGE
PAR 2 -induced COX-2 expression requires a secreted factor. Culture media from postconfluent Caco-2 cells treated with 2fLI or with RP were filtered through spin columns with a molecular weight cut-off of 3-10 kDa to remove any remaining 2fLI peptide (molecular weight of 2fLI is 778 Da). Treatment of naïve cells with concentrated conditioned media also led to an increase in cellular COX-2 protein levels ( Fig. 2A) . In separate experiments using the same protocol, the concentrated conditioned media were subjected to HPLC to confirm that intact 2fLI was no longer present (no peak at arrow, where 2fLI is eluted; Fig. 2B) .
PAR 2 -induced COX-2 expression is mediated by metalloproteinase activity. Greater metalloproteinase activity was observed in media from Caco-2 cells treated for 30 min with 2fLI than in untreated cells (Fig. 3A) . This increased metalloproteinase activity was not likely attributable to an increase in transcriptional regulation of metalloproteinases, as preliminary evidence from a DNA microarray to assess the human degradome (21) and associated inhibitors revealed no significant changes in any of the genes for metalloproteinases or their endogenous inhibitors (data not shown). Pretreatment of Caco-2 cells with the broad-spectrum metalloproteinase inhibitor marimastat concentration dependently prevented the PAR 2 -mediated COX-2 expression (Fig. 3, B and C) . Pretreatment with either ARP 100 (100 nM or 1 M), an inhibitor more selective for MMP-2, or with TIMP-1 (200 ng), an endogenous MMP inhibitor with more selectivity toward MMP-9, did not Fig. 2 . A: media from cells treated with either RP or 2fLI for 3 h were filtered through a concentrating spin column to remove 2fLI. Resulting concentrated conditioned media were used to treat separate cells for 3 h. COX-2 and actin levels were assessed as in Fig. 1 . Results shown represent 4 separate experiments, *P Ͻ 0.05 compared with RP treatment group. B: peak absorbance was measured at 254 nm in media samples eluted through a high-performance liquid chromatography column. 2fLI-treated samples were spiked with 0.5 M RP as an internal standard (RP Std). Arrow points to the expected elution time for 2fLI. Inset: peaks of RP and 2fLI in nonconditioned, serum-free medium.
affect the PAR 2 -induced COX-2 expression (Fig. 3C) . Furthermore, direct treatment of cells with activated recombinant human MMP-9 (10 ng or 25 ng) did not lead to a significant increase in COX-2 expression (Fig. 3D) .
EGFR activity is required for PAR 2 -mediated COX-2 expression. Treatment of Caco-2 cells with 2fLI led to an increase in tyrosine phosphorylation of the EGFR that was most evident at 40 min (Fig. 4A) . This increase in EGFR activity could be reduced with marimastat (3 M) but not with PD98059 (20 M), which prevents signaling through the ERK/MAPK pathway, a pathway known to be activated following PAR 2 stimulation (Fig. 4B) . Pretreatment of cells with the selective EGFR tyrosine kinase inhibitor PD153035 (1 M) completely prevented the PAR 2 -induced COX-2 expression (Fig. 4C) . Because metalloproteinases were required for the increased COX-2 expression and because these enzymes are capable of cleaving membrane-bound growth factors, we did a preliminary multiplex assessment of the levels of EGFR ligands, as well as EGFR itself, expressed on or secreted by Caco-2 cells stimulated or not with the PAR 2 -activating peptide in the presence or absence of the metalloproteinase inhibitor marimastat. As expected, lysates from Caco-2 cells contained a relatively high level of the EGFR itself (Fig. 5A, middle) . Amphiregulin and heparin-binding-EGF were the only EGFR ligands that were detected in Caco-2 cell lysates, but only amphiregulin could be detected in conditioned media from Caco-2 cells (Fig. 5A, top) . Betacellulin, EGF, epiregulin, and TGF-␣ were not detected in either lysates or conditioned cell media from Caco-2 cells (data not shown). We performed an amphiregulin-specific ELISA assay and found that, whereas PAR 2 activation did not increase amphiregulin in the conditioned media, activation of PAR 2 in the presence of marimastat did significantly diminish the amphiregulin detected in the conditioned media (Fig. 5B) .
ERK and p38 MAPK signaling are not required for PAR 2 -mediated COX-2 expression, whereas Src tyrosine kinase is required. PAR 2 activation led to a rapid and sustained increase in ERK phosphorylation that appears somewhat biphasic in nature (Fig. 6A) and persists up to at least 3 h following treatment (not shown). However, pretreatment of cells with PD98059 (20 M) or with another ERK-MAPK pathway inhibitor, U0126 (1 M or 10 M), which blocked MAPK activation (not shown), did not significantly prevent PAR 2 -induced COX-2 expression (Fig. 6B, left) . An inhibitor of p38 MAPK, SB202190 (1 M), also failed to affect PAR 2 -induced COX-2 expression (Fig. 6B, right) . In other model systems, transactivation of the EGFR can occur through the intracellular Lysates were probed for COX-2 and actin. Densitometry was performed on the bands, and results are expressed as the ratio of COX-2 to actin normalized to 2fLI only (2nd column); n ϭ 5-16, ***P Ͻ 0.001 compared with RP, ###P Ͻ 0.001 compared with 2fLI. D: Caco-2 cells were treated with recombinant human MMP-9 that had been preactivated with aminophenylmercuric acetate or with the vehicle containing the same concentration of aminophenylmercuric acetate (Veh) for 3 h. Lysates were probed for COX-2 and actin. Immunoblots were analyzed via densitometry, and results are expressed as a ratio of COX-2 to actin, normalized to the vehicle control; n ϭ 3. Fig. 4 . A: Caco-2 cells were left untreated (Ctrl) or were treated with 0.5 M 2fLI for various times. As a positive control for epidermal growth factor receptor (EGFR) activation, some cells were treated with 50 ng/ml EGF for 5 min. Cell lysates were immunoprecipitated with 4 g anti-EGFR antibody or nonspecific IgG (IP: negative), then immunoblotted for phospho-tyrosine (top). The membrane was then stripped and reprobed for total EGFR expression (bottom). Three separate experiments using Caco-2 whole cell extracts confirmed an increase in phosphorylated tyrosine at a size matching that of EGFR (ϳ175 kDa) following 40 min of treatment with 2fLI. B: Caco-2 cells were left untreated (Ctrl) or were treated with 0.5 M 2fLI for 40 min in the presence or absence of marimastat (3 M) or PD98059 (20 M). Cell lysates were immunoprecipitated with 4 g anti-EGFR antibody or nonspecific IgG (added to EGF-treated cell lysates, IP: negative), then immunoblotted as in A. The ability of marimastat to reduce phosphorylated EGFR was supported by an additional immunoprecipitation experiment as well as by 3 separate experiments using Caco-2 whole cell extracts as in A. C: Caco-2 cells were treated for 3 h with 0.5 M RP or 2fLI in the presence or absence of the EGFR inhibitor PD153035 (1 M). Lysates were probed for COX-2 and actin (top). Immunoblots (IB) were analyzed via densitometry, and results are expressed as a ratio of COX-2 to actin, normalized to 2fLI only (2nd column, bottom). ***P Ͻ 0.001 compared with RP; ###P Ͻ 0.001 compared with 2fLI. n ϭ 3-5. nonreceptor tyrosine kinase Src (40) . In keeping with this, the selective Src inhibitor, PP2, concentration dependently reduced PAR 2 -induced COX-2 expression (Fig. 6C) .
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Rho kinase and PI3 kinase signaling are each required for PAR 2 -mediated COX-2 expression. In addition to activating ERK MAPK signaling, others have shown that PAR 2 activation can signal through the Rho family of small GTPases (45) . Pretreatment of Caco-2 cells with the Rho kinase-selective inhibitor Y27632 (20 M) significantly attenuated the PAR 2 -induced COX-2 expression (Fig. 7A) . Furthermore, pretreatment of cells with the PI3 kinase-selective inhibitor LY294002 (30 M) also significantly inhibited the PAR 2 -induced COX-2 expression (Fig. 7B) , an effect that appeared to be concentration dependent (Fig. 7B, top) .
Trypsin increases COX-2 expression via activation of PAR 2 . Treatment of Caco-2 cells with trypsin (45 BA U/ml) for 3 h led to an increase in COX-2 expression similar to that observed following treatment with 2fLI (Fig. 8A) . Transient knockdown of PAR 2 using specific siRNA prevented both the trypsininduced and the 2fLI-induced increase in COX-2 expression in Caco-2 cells (Fig. 8A) , supporting the hypothesis that in vivo activation of PAR 2 by serine proteinases can upregulate COX-2 expression.
Trypsin increases COX-2 expression in an EGFR-dependent manner in noncancerous IECs.
Treatment of IEC-6 cells, which are undifferentiated nontumorigenic normal intestinal epithelial cells derived from the rat small intestine (30) , with trypsin for 3 h significantly increased COX-2 expression in these cells, a process that was also sensitive to inhibition with the EGFR inhibitor PD153035 (Fig. 8B) .
DISCUSSION
It is now widely accepted that EGFR transactivation in response to the activation of G protein-coupled receptors occurs in a large number of cancer cells, and it is believed that this is an important cancer-signaling pathway (3). There is a growing body of literature describing the ability of PAR 2 to transactivate the EGFR in several cell types (7, 22, 25) , including colon cancer cells (11, 19, 40) . Our results are, to our knowledge, the first to link PAR 2 activation to COX-2 expres- Fig. 6 . A: Caco-2 cells were treated with 0.5 M 2fLI for the indicated times. Lysates were probed for phosphorylated ERK 1/2 (p-ERK) and total ERK 1/2 (t-ERK; left). Immunoblots were analyzed via densitometry, and results are expressed as a ratio of phospho-ERK to total ERK (right); n ϭ 3, except for 50-min time point, where n ϭ 2. B: Caco-2 cells were left untreated (Ctrl) or were treated with 0.5 M 2fLI for 3 h in the presence or absence of the MEK inhibitors U0126 or PD98059 (left) or in the presence or absence of the p38 MAPK inhibitor SB202190 (right). Lysates were probed for COX-2 and actin. Left: immunoblots were analyzed via densitometry, and results are expressed as a ratio of COX-2 to actin normalized to 2fLI only (2nd column); *P Ͻ 0.05, ***P Ͻ 0.001 compared with Ctrl, n ϭ 4 -8. Right: representative of 3 separate experiments. C: Caco-2 cells were left untreated (Ctrl) or were treated with 0.5 M 2fLI or 0.5 M RP for 3 h in the presence or absence of the Src tyrosine kinase inhibitor PP2. Lysates were probed for COX-2 and actin. Immunoblots were analyzed via densitometry, and results are expressed as a ratio of COX-2 to actin normalized to 2fLI only (4th column); **P Ͻ 0.01 compared with either Ctrl, 1 M PP2 or RP, ##P Ͻ 0.01 compared with 2fLI or 300 nM PP2 ϩ 2fLI, n ϭ 4 -14. sion in IECs. Interestingly, this link is not present in cells grown just to confluence, which is likely a reflection of the threefold lower level of PAR 2 expression during this period compared with the level observed during the postconfluent differentiation period. Also, in our model, EGFR transactivation appears to occur at a much later time point than what is reported in the literature for other colon cancer cell lines. This delay may be attributable to the requirement for increased metalloproteinase activity, which was observed following 30 min of treatment with the PAR 2 -activating peptide, 2fLI. The inhibitory actions of the metalloproteinase inhibitor, marimastat, and the selective EGFR-kinase inhibitor, PD153035, to block COX-2 expression induced by PAR 2 activation in Caco-2 cells indicate a metalloproteinase-mediated transactivation of the EGFR as described previously (13) . Our data can rule out a role for the gelatinases MMP-2 and MMP-9 and point to the rapid activation of a marimastat-sensitive prometalloproteinase, rather than to transcriptional upregulation of a metalloproteinase. Others have reported increased MMP-9 synthesis, expression, and secretion in lung epithelium and gingival tissue at time points ranging from 4 h to 7 days following PAR 2 activation (18, 44) . However, as mentioned, MMP-9 does not appear to be involved in PAR 2 -induced COX-2 expression in Caco-2 cells, as the MMP-9-selective inhibitor TIMP-1 failed to prevent COX-2 induction and direct treatment of cells with activated MMP-9 did not significantly alter COX-2 expression in these cells. The identity of the marimastat-sensitive MMP that is involved in the upregulation of COX-2 in Caco-2 cells remains to be determined.
Intracellularly, PAR 2 activation has been linked to increased Ca 2ϩ levels and MAPK pathway activation through Ras. It has also been linked to Src kinase, Rho GTPase, NF-B, PKC, and PI3 kinase activation (40, reviewed in Ref. 32) . In A549 lung cancer cells, our laboratory has shown that activating PAR 2 with the activating peptide SLIGRL-NH 2 induces COX-2 expression and PGE 2 production through ERK-dependent inactivation of GSK-3␤ and subsequent activation of the ␤-catenin/ TCF-4/CREB transcriptional pathway (47) . Earlier on, Kawao et al. (22) had shown that ERK MAPK signaling, while important in PAR 2 -induced PGE 2 production from A549 cells, was not required for the increased COX-2 expression in these cells (22) . Instead, p38 was the important MAPK for both PAR 2 -induced COX-2 expression and PGE 2 production. It is interesting to note that, for most of their experiments, Kawao et al. (22) used a higher concentration of SLIGRL-NH 2 (100 M vs. 50 M); at 100 M, Wang et al. (47) showed that SLIGRL-NH 2 was capable of transcriptionally activating NF-B as well as ␤-catenin, whereas 50 M SLIGRL-NH 2 was able to activate ␤-catenin-driven, but not NF-B-driven, transcription. Because the EC 50 value for 2fLI in Ca 2ϩ mobilization assays is ϳ10-fold lower than for SLIGRL-NH 2 (20) , it is quite likely that the low concentration (0.5 M) of 2fLI used in our study does not activate NF-B-driven gene transcription in Caco-2 cells. To this end, preliminary experiments did not show an increase in B-driven luciferase activity following treatment of transfected Caco-2 cells with 2fLI (data not shown). or DMSO vehicle (Veh); n ϭ 7. Lysates were probed for COX-2 and actin. Bottom: band density was measured, and results are expressed as the ratio of COX-2 to actin normalized to 2fLI only (middle bar). ***P Ͻ 0.001 compared with RP; ##P Ͻ 0.01 compared with 2fLI. Fig. 8 . A: Caco-2 cells were lifted with EDTA and replated in serum-free and antibiotic-free media containing 50 nM siRNA directed against PAR2 (PAR2 siRNA), 50 nM scrambled nonsense RNA (Scr RNA), or no RNA. 24 h later, cells were treated with 0.5 M RP, 45 biological activity units (BAU)/ml trypsin, or with 0.5 M 2fLI for 3 h. Cell lysates were probed for COX-2 and actin (left). Band density was measured and expressed as a ratio of COX-2/actin (middle); *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 as indicated, n ϭ 3. Successful PAR2 knockdown was confirmed with real-time reverse transcription PCR (right). mRNA from Caco-2 cells transfected as above with PAR2 siRNA, Scr RNA, or no RNA (1 well per each transfection condition) was amplified with PAR2-specific primers or ␤-actin-specific primers (see above for primer sequences). Right: ratio of PAR2/actin mRNA normalized to cells transfected with Scr RNA and expressed as means Ϯ SD of a triplicate PCR reaction. B: intestinal epithelial cell (IEC)-6 cells were grown for 4 days and serum starved for 1 h. 1 M PD153035 or an equal volume of DMSO was added 5 min before treatment with 0.5 M RP or 45 BAU/ml trypsin for 3 h. Cell lysates were probed for COX-2 and actin. Band density was measured and expressed as a ratio of COX-2/actin; ***P Ͻ 0.001 compared with DMSO ϩ RP or PD153035 ϩ RP, ##P Ͻ 0.01 compared with DMSO ϩ trypsin, n ϭ 4.
The strong ERK MAPK activation we observed following treatment with 2fLI in the Caco-2 cells did not seem to be required for PAR 2 -induced COX-2 expression, nor did we find a role for p38 MAPK. ERK-MAPK signaling is a known downstream signaling pathway for the EGFR, and the somewhat biphasic nature of ERK activation in our model is a likely indication of this process. Indeed, an EGFR tyrosine kinase inhibitor was able to prevent ERK activation in our model (data not shown). The intracellular nonreceptor tyrosine kinase Src has previously been linked to PAR 2 -induced EGFR transactivation in other IEC lines (11, 19, 40) . Indeed, the Src inhibitor PP2 concentration dependently prevented the upregulation of COX-2 in Caco-2 cells, suggesting an intracellular transactivation link between PAR 2 and EGFR in addition to the extracellular metalloproteinase-dependent mechanism of transactivation. There are several reports of PAR 2 signaling through the Rho family of small GTPases, leading to downstream activation of Rho kinase (15, 45, 49) . Interestingly, hyperactivation of RhoA (upstream of Rho kinase) cooperates with the Ras/ Raf/MAPK signaling pathway to transform IECs and drive COX-2 expression (14) . Hyperactivation of the PI3 kinase signaling pathway is also a common observation in several malignancies, including colon cancer (reviewed in Refs. 35 and 50) . It has even been proposed that PI3 kinase signaling during inflammation may participate in driving the progression from chronic intestinal inflammation to cancer (48) . PI3 kinase signaling has been implicated in both PAR 2 -induced PGE 2 production (although not COX-2 expression) in lung cancer cells and PAR 2 -induced IL-8 secretion in colon cancer cells (27, 39) . Thus the requirement for Src, Rho, and PI3 kinase activity in driving PAR 2 -mediated COX-2 expression in Caco-2 cells provides a further link between PAR 2 activation and oncogenic signaling pathways in the context of colon cancer.
Overall our data support a role for PAR 2 in promoting epithelial cell survival, proliferation, and transformation, a common theme in the PAR 2 literature. However, our data show differences in signaling following PAR 2 activation that leads to COX-2 induction when comparing the Caco-2 cells with previous data obtained using lung-derived A549 cells (22, 47) . Our new results emphasize the importance of cell-specific coupling of the receptor to intracellular signals. In vivo, this process is complicated by the potential presence in the external environment of serine proteinases that can differentially activate PAR 2 signaling (33). In the context of intestinal inflammation, however, PAR 2 does appear to be overexpressed in the colonic epithelium from patients with Crohn's disease, and it can be activated by serine proteinases derived from neutrophils (10) . Furthermore, several reports indicate that both luminal and mucosal proteinase concentrations (serine proteinases in particular) are increased in patients with IBD, especially those with ulcerative colitis, compared with noninflamed controls (6, 24, 31) . In our model, we have shown that the prototypical PAR 2 -activating serine proteinase trypsin is also capable of increasing epithelial COX-2 expression through PAR 2 , and, importantly, this phenomenon occurs in a noncancerous IEC line via activation of the EGFR as well, providing greater in vivo relevance to this signaling pathway.
In summary, we have shown that activation of PAR 2 in a colonic epithelial cancer cell line stimulates the expression of COX-2 via a mechanism that requires metalloproteinase-dependent EGFR transactivation and both Rho kinase and PI3 kinase activity. Our results have important implications for the development of colon cancer in the context of inflammatory bowel disease, and they provide further mechanistic support for the inhibition of both COX-2 and EGFR as a more effective treatment strategy for colon cancer than either therapy alone. Future work to determine the specific metalloproteinase required for this process will also be of great therapeutic value for colon cancer.
